Teva prices approximately $4.9 billion equivalent in senior notes

Teva Pharmaceutical Industries Limited announced successful pricing of approximately $4.9 billion (equivalent) of senior notes in a September 10 press release, following an underwriting agreement signed September 9. The offering spans five tranches issued by three Netherlands finance subsidiaries, with Teva acting as guarantor. Settlement is expected on or about September 16, 2026, subject to customary closing conditions, according to the company's Form 8-K filed September 11 (Form 8-K AccNo 0001193125-26-389264).

CONTEXT: The transaction is priced, with an underwriting agreement signed; that d

The transaction is priced, with an underwriting agreement signed; that does not establish that it has closed or that cash has been received. The company's approximately $4.9 billion equivalent description combines euro and U.S. dollar tranches. It is neither a single U.S. dollar principal amount nor a statement of net proceeds after underwriting discounts and offering expenses. The disclosed chronology places the agreement, announcement and filing on September 9, 10 and 11, respectively.

FACT: Teva Pharmaceutical Finance Netherlands II B

Teva Pharmaceutical Finance Netherlands II B.V. is offering €1 billion of 4.250% senior notes due 2033 and €500 million of 4.625% senior notes due 2036. Their issue prices are 98.756% and 98.327% of principal, respectively. Teva Pharmaceutical Finance Netherlands III B.V. is offering $1 billion of 5.500% senior notes due 2034 at 98.659% of principal and $1 billion of 5.750% senior notes due 2037 at 98.520%. Teva Pharmaceutical Finance Netherlands IV B.V. is offering $1.2 billion of 5.250% senior notes due 2032 at 98.993% of principal.

CONTEXT: Each issue price is below 100% of principal, meaning all five tranches a

Each issue price is below 100% of principal, meaning all five tranches are priced at a discount to face value. Those percentages are issue prices, distinct from the stated annual coupon rates. They should not be presented as aggregate net proceeds: Form 8-K AccNo 0001193125-26-389264 does not give a single net-proceeds total after underwriting discounts and offering expenses.

FACT: The notes will be senior unsecured obligations of their respective issue

The notes will be senior unsecured obligations of their respective issuers and will carry Teva's unconditional guarantee on a senior unsecured basis. Teva expects to apply net proceeds, together with cash on hand, to conditional redemptions of existing notes and associated fees and expenses. Any remaining proceeds are intended for general corporate purposes, including repayment of outstanding debt at maturity, through a tender offer or by earlier redemption. Proceeds may be temporarily invested before application.

FACT: The company issued conditional redemption notices September 8 covering a

The company issued conditional redemption notices September 8 covering all outstanding 6.750% senior notes due 2028, all outstanding 7.875% and 7.375% sustainability-linked senior notes due 2029, up to $450 million of 4.750% sustainability-linked senior notes due 2027, and up to €1.25 billion of 4.375% sustainability-linked senior notes due 2030. These notices describe intended redemptions under the relevant indentures.

FACT: In its September 10 release, Teva also said it expected that day to issu

In its September 10 release, Teva also said it expected that day to issue an additional conditional redemption notice for all of its 8.125% U.S. dollar sustainability-linked senior notes due 2031. It expected a separate notice to reduce the intended redemption of the 4.375% notes due 2030 from up to €1.25 billion to €1.15 billion. The release retained prospective language for those steps. Teva may issue additional notices or amend principal amounts in its sole discretion and is under no obligation to do so.

CONTEXT: The financing therefore connects new debt pricing with an intended refin

The financing therefore connects new debt pricing with an intended refinancing program, but conditional notices do not establish completed redemptions. The release says settlement of the new notes in the indicated amount will satisfy the redemptions' funding condition: the applicable issuers must receive funding satisfactory to them and sufficient to cover redemption prices and related expenses. That remains a condition tied to settlement, rather than evidence that either transaction has finished.

UNKNOWN: Form 8-K AccNo 0001193125-26-389264 do not establish completed settlemen

Form 8-K AccNo 0001193125-26-389264 do not establish completed settlement, completed conditional redemptions or final redeemed principal amounts. They also do not provide a single aggregate net-proceeds figure or explain the foreign-exchange methodology behind the company's approximate dollar-equivalent sizing. The next transaction milestone identified in the disclosure is expected settlement on or about September 16, subject to customary closing conditions.